Skip to main content

Specific Antibody Deficiency

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
Diagnosis of SPAD using immunization with PPV23N/A1 trial
Active Trials
NCT05664035Not Yet Recruiting99Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
TakedaDiagnosis of SPAD using immunization with PPV23

Clinical Trials (1)

Total enrollment: 99 patients across 1 trials

NCT05664035TakedaDiagnosis of SPAD using immunization with PPV23

SPAD in Adult Patients

Start: Mar 2023Est. completion: Jun 202699 patients
N/ANot Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.